Pfizer "regrets" offending Harvard students; FDA advisory panel talks Seroquel April 8;

> Pfizer issued a statement saying it regrets if anyone was offended when a company sales rep photographed Harvard Medical School students protesting industry influence on campus. Report

> To compete with Bristol-Myers Squibb and Sanofi-Avenits's clotbuster Plavix in Europe, Eli Lilly will need to mount an aggressive marketing campaign for its newly-approved-in-the-EU drug Prasugrel, industry experts said. Report 

> The FDA will ask an advisory panel for advice on whether the agency should allow wider use of AstraZeneca's Seroquel, which is currently approved to treat bipolar disorder and schizophrenia; the meeting is tentatively scheduled for April 8. Report

> Teva Pharmaceutical has seen big growth in prescriptions of its Parkinson's treatment Azilect as neurologists get more comfortable with the drug, a Decision Resources study found. Report

> Pharmacies around the country are offering free antibiotics to cash-strapped consumers, but public health officials say the incentives send the wrong message and could worsen the problem of drug resistance. Report

> Left reeling from the FDA's rejection of its imaging drug in December, Acusphere is chopping 40 jobs--roughly two thirds of its remaining staff--in a restructuring that also includes the close of its Watertown, MA headquarters. Report

> Alnylam Pharmaceuticals and Isis Pharmaceuticals have chipped in $20 million to fund the Series A round of Regulus Therapeutics, their RNA spin-off. Report

> A struggling Pharmexa and Affitech have struck a deal to merge into a new company that will focus on new antibody therapeutics. Report

> With its closely-watched hep C drug telaprevir working its way toward an FDA filing, Vertex Pharmaceuticals announced that it is buying Canada's ViroChem Pharma for $375 million in cash and stock. Report

> Index Ventures has just closed a $438.8 million fund, with a big chunk of that slated for biotech companies with a lot to offer in the pipeline. Report

> A team of researchers led by Scripps Professor Carlos Barbas, III, Ph.D., report a new method of vaccination can provide instant protection against a pathogen. Report

> FluMist just got a big thumb's down in a study reviewing vaccine response in more than a million U.S. soldiers. Report

And Finally... Curious how Roche handles IT? Check out this podcast with its CIO. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.